WAILEA, Hawaii — Canaloplasty has shown through the years to be a safe and effective procedure for primary open-angle glaucoma, but more evidence from well-designed studies is needed to support reimbursement, according to one specialist.
Following the recent local coverage determination (LCD) changes proposed for Medicare reimbursement, current and future MIGS procedures, including canaloplasty, must be FDA approved and demonstrate effectiveness of 20% or greater IOP reduction over 24 months by moderate-high quality literature.
“[A lot] of the studies [on canaloplasty] are